Clinical trial Recruiting at 1 site Observational Ages 18 to 80

When and how people recover after an intracerebral hemorrhage

Official title: Timing and Outcomes of Recovery After intraCerebral Hemorrhage

Run by Xuanwu Hospital, Beijing · NCT07166146 · Data updated 2026-11-12

This registry will collect detailed, long-term data on adults who have surgery for intracerebral hemorrhage to see if the timing and type of surgical treatment affect recovery and quality of life.

More Intracerebral Hemorrhage trials

Quick facts

Study typeObservational
Ages18 Years to 80 Years
SexAll
Enrollment500 (estimated)
SponsorXuanwu Hospital, Beijing
Academic / other
Locations1 site (Beijing)
StatusRecruiting
StartedJune 4, 2025
Main results expectedMarch 15, 2027
Study endsMarch 15, 2028
Registry record updatedSeptember 10, 2025
Trial IDNCT07166146 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Adults aged 18–80 with an acute primary supratentorial intracerebral hemorrhage who undergo a surgical intervention and have baseline mRS ≤1 and NIHSS ≥6 or GCS 5–15 are ideal candidates.

Probably not a fit

Patients with secondary causes of intracerebral hemorrhage, irreversible coagulopathy, very limited life expectancy from other illnesses, or those not receiving surgery are unlikely to benefit from participation.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

The TORCH registry is a prospective, observational cohort enrolling adults with acute, spontaneous supratentorial intracerebral hemorrhage who receive surgical treatment at Xuanwu Hospital. It will collect standardized, longitudinal data on clinical presentation, imaging (CT/CTA), surgical modality (including endoscopic evacuation, minimally invasive surgery with urokinase, and craniotomy), timing of intervention, and functional and quality-of-life outcomes. Eligibility includes age 18–80, baseline mRS ≤1, and defined severity thresholds (NIHSS ≥6 or GCS 5–15); patients with secondary causes of hemorrhage or irreversible coagulopathy are excluded. By comparing outcomes across interventions and timing, the registry aims to produce granular, real-world evidence to guide surgical decision-making.

Why it matters

Potential benefit: If successful, the registry could identify which surgical approaches and timing are linked to better recovery and quality of life, helping guide future treatment choices.

How similar studies have gone: Previous randomized and observational efforts of minimally invasive and endoscopic hematoma evacuation have shown mixed results—some reduce hematoma volume but have not consistently produced clear functional benefit—so comparative registry data remain valuable and relatively novel.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

* Subject Age is ≥18 to ≤80 years
* Subject with a Head CT/CTA that demonstrates an acute, spontaneous, primary, supratentorial ICH, assessed via standard of care techniques
* Subject recieving a surgery intervention
* Subject has a NIHSS score ≥ 6 or GCS score 5≤GCS≤15
* Subject has a baseline Modified Rankin Scale (mRS) Score ≤ 1

Exclusion Criteria:

* Secondary intracerebral hemorrhage (with leading cause, e.g., Moyamoya disease, arteriovenous malformation, intracranial aneurysm, tumor, brain trauma)
* Pre-stroke life expectancy \< 1 year for severe comorbidities (e.g., Progressive malignant tumor, severe chronic heart failure \[NYHA: III-IV\], severe chronic obstructive pulmonary disease \[III-IV\], chronic kidney disease requiring hemodialysis)
* Patients with platelet count \< 100,000, INR \> 1.4, or an elevated PT or APTT (reversal of coumadin is permitted but the patient must not require coumadin during the acute hospitalization). Irreversible coagulopathy either due to medical condition or prior to randomization
* Pregnant (positive pregnancy test) or lactating females (likelihood of altered coagulation function associated with the high estrogen/progesterone state)
* Irreversibly impaired brainstem function (bilateral fixed, dilated pupils and extensor motor posturing), GCS less than or equal to 4

Where it's running

  • The Department of Neurosurgery, China International Neuroscience Institute, Xuanwu Hospital, Capital Medical University,
    Beijing, China
    Recruiting

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.